Fluorine-18-labeled fluciclovine PET/CT in primary and biochemical recurrent prostate cancer management

Charles Marcus; Peter Butler; Aditya Bagrodia; Suzanne Cole; Rathan M. Subramaniam

doi:10.2214/AJR.19.22404

Fluorine-18-labeled fluciclovine PET/CT in primary and biochemical recurrent prostate cancer management

Charles Marcus, Peter Butler, Aditya Bagrodia, Suzanne Cole, Rathan M. Subramaniam

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

Objective: The purpose of this article is to review the utility of 18F-fluciclovine PET/CT in the evaluation of recurrent prostate cancer. COnclusion: Fluorine-18-labeled fluciclovine PET/CT has shown promise in the evaluation of recurrent prostate cancer. Its performance has been superior to that of other imaging modalities. It has had good diagnostic accuracy, especially in the detection of extraprostatic disease recurrence, and the findings have an impact on treatment planning. Gallium-68-labeled prostate-specific membrane antigen PET/CT has also had excellent performance in the detection of biochemically recurrent prostate cancer with detection rates superior to those of fluciclovine PET/CT.

Original language	English (US)
Pages (from-to)	267-276
Number of pages	10
Journal	American Journal of Roentgenology
Volume	215
Issue number	2
DOIs	https://doi.org/10.2214/AJR.19.22404
State	Published - Aug 2020

Keywords

Fluciclovine
PET/CT
Primary
Prostate cancer
Recurrent

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.2214/AJR.19.22404

Cite this

@article{63833f48882c47c6a4edd22b262068b4,

title = "Fluorine-18-labeled fluciclovine PET/CT in primary and biochemical recurrent prostate cancer management",

abstract = "Objective: The purpose of this article is to review the utility of 18F-fluciclovine PET/CT in the evaluation of recurrent prostate cancer. COnclusion: Fluorine-18-labeled fluciclovine PET/CT has shown promise in the evaluation of recurrent prostate cancer. Its performance has been superior to that of other imaging modalities. It has had good diagnostic accuracy, especially in the detection of extraprostatic disease recurrence, and the findings have an impact on treatment planning. Gallium-68-labeled prostate-specific membrane antigen PET/CT has also had excellent performance in the detection of biochemically recurrent prostate cancer with detection rates superior to those of fluciclovine PET/CT.",

keywords = "Fluciclovine, PET/CT, Primary, Prostate cancer, Recurrent",

author = "Charles Marcus and Peter Butler and Aditya Bagrodia and Suzanne Cole and Subramaniam, {Rathan M.}",

note = "Publisher Copyright: {\textcopyright} 2020 American Roentgen Ray Society.",

year = "2020",

month = aug,

doi = "10.2214/AJR.19.22404",

language = "English (US)",

volume = "215",

pages = "267--276",

journal = "American Journal of Roentgenology",

issn = "0361-803X",

publisher = "American Roentgen Ray Society",

number = "2",

}

TY - JOUR

T1 - Fluorine-18-labeled fluciclovine PET/CT in primary and biochemical recurrent prostate cancer management

AU - Marcus, Charles

AU - Butler, Peter

AU - Bagrodia, Aditya

AU - Cole, Suzanne

AU - Subramaniam, Rathan M.

PY - 2020/8

Y1 - 2020/8

N2 - Objective: The purpose of this article is to review the utility of 18F-fluciclovine PET/CT in the evaluation of recurrent prostate cancer. COnclusion: Fluorine-18-labeled fluciclovine PET/CT has shown promise in the evaluation of recurrent prostate cancer. Its performance has been superior to that of other imaging modalities. It has had good diagnostic accuracy, especially in the detection of extraprostatic disease recurrence, and the findings have an impact on treatment planning. Gallium-68-labeled prostate-specific membrane antigen PET/CT has also had excellent performance in the detection of biochemically recurrent prostate cancer with detection rates superior to those of fluciclovine PET/CT.

AB - Objective: The purpose of this article is to review the utility of 18F-fluciclovine PET/CT in the evaluation of recurrent prostate cancer. COnclusion: Fluorine-18-labeled fluciclovine PET/CT has shown promise in the evaluation of recurrent prostate cancer. Its performance has been superior to that of other imaging modalities. It has had good diagnostic accuracy, especially in the detection of extraprostatic disease recurrence, and the findings have an impact on treatment planning. Gallium-68-labeled prostate-specific membrane antigen PET/CT has also had excellent performance in the detection of biochemically recurrent prostate cancer with detection rates superior to those of fluciclovine PET/CT.

KW - Fluciclovine

KW - PET/CT

KW - Primary

KW - Prostate cancer

KW - Recurrent

UR - http://www.scopus.com/inward/record.url?scp=85089162465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089162465&partnerID=8YFLogxK

U2 - 10.2214/AJR.19.22404

DO - 10.2214/AJR.19.22404

M3 - Review article

C2 - 32551903

AN - SCOPUS:85089162465

SN - 0361-803X

VL - 215

SP - 267

EP - 276

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

IS - 2

ER -

Fluorine-18-labeled fluciclovine PET/CT in primary and biochemical recurrent prostate cancer management

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this